ライフサイエンスコーパス: PGD2

1 ing abundant production of prostaglandin D2 (PGD2).

2 F(2alpha) (PGF2alpha), and prostaglandin D2 (PGD2).

3 synthesis and secretion of prostaglandin D2 (PGD2).

4 ive with the native agonist prostaglandin D2(PGD2).

5 all but statistically significant release of PGD2.

6 ggerated migratory response of cells against PGD2.

7 ed by nicotinic acid but not that induced by PGD2.

8 D2c-IsoP) would be predicted to rearrange to PGD2.

9 Mutation in CRE eliminated the response to PGD2.

10 bited CREB activation and c-fos induction by PGD2.

11 supply of arachidonic acid for metabolism to PGD2.

12 stidic localization of PGD1 and PGD3 but not PGD2.

13 l unit reacting to inflammation by producing PGD2.

14 s in the quartet1-2 background revealed that pgd2-1 pollen is vital and in vitro germination normal,

15 ailed analyses of the C-terminally truncated PGD2-1 protein showed that peroxisomal import and cataly

16 Reciprocal backcrosses of pgd2-1 suggested that missing PGD activity in peroxisome

17 ed vasodilation; the DP2-specific agonist DK-PGD2 (13,14-dihydro-15-keto-PGD2) did not induce cutaneo

18 d COX1/ALOX15/ALOX5/LTA4H(low) gene and PGE2/PGD2/15-HETE(high) and LXA4(low) eicosanoid profile.

19 The first total synthesis of 15(R)-Me-PGD2 3 is reported.

20 nd high-affinity uptake of PGE2, PGF2 alpha, PGD2, 8-iso-PGF2 alpha, and thromboxane B2.

21 produced by dehydration and isomerization of PGD2, a cyclooxygenase product.

22 Prostaglandin D2 (PGD2) acting at the CRTH2 receptor (chemoattractant rece

23 d to assess whether pesticides identified as PGD2-active could serve as ligands of the cyclooxygenase

24 These analyses showed that peroxisomal PGD2 activity is required for guided growth of the male

25 d and water and find that the binding of the PGD2 agonist leads to correlated rotations of helices of

26 PGD2 also increased Fos immunoreactivity in the basal le

27 Catalytic activity of L-PGDS produces PGD2, an endogenous somnogen.

28 CRTH2 internalized upon treatment with PGD2 and 11-dehydro TXB2 in eosinophils of controls.

29 stromal cell L-PGDS included high levels of PGD2 and 15-deoxy-delta(12,14)-PGD2 but low levels of 15

30 CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7H6, respectively.

31 The combination of PGD2 and cysLTs (notably cysteinyl leukotriene E4 [LTE4]

32 icantly reduces antigen-induced secretion of PGD2 and cysteinyl-leukotriene.

33 etin (TSLP) acting on mast cells to generate PGD2 and facilitate tissue eosinophilia and nasal polypo

34 In this setting, PGD2 and its enantiomer generated by the IsoP pathway re

35 PGD2 and LTE4 activate TH2 cells through different pathw

36 PGD2 and LTE4 altered the transcription of a wide range

37 Combined inhibition of both PGD2 and LTE4 pathways might provide an effective therap

38 Blockade of PGD2 and LTE4 was tested by using TM30089, an antagonist

39 naling molecules by means of immunoblotting, PGD2 and macrophage inflammatory protein 1beta generatio

40 HF, and demonstrates a possible link between PGD2 and perturbed proliferation dynamics in epithelial

41 COX-2-derived PGD2 and PGE2 regulate Th9 cell differentiation by suppr

42 IL-17RB expression in vivo was inhibited by PGD2 and PGE2, which also reduced Th9 cell differentiati

43 Thus, combined treatment with PGD2 and RA substantially decreased tumor growth in huma

44 pounds identical in all respects to PGE2 and PGD2 and their respective enantiomers are generated in v

45 d by palmitic acid were mimicked by PGE2 and PGD2 and were reversed by cyclooxygenase inhibition or p

46 (LT)E4 , induced sputum fluid LTB4 , LTE4 , PGD2 , and PGE2 , plasma secretory phospholipase A2 (sPL

47 nations of plasmid vector that expresses gD (pgD2) and a recombinant modified vaccinia virus Ankara v

48 Prostaglandin D2 (PGD2) and cysteinyl leukotrienes (cysLTs) are lipid medi

49 e enzyme (L-PGDS) that produces its agonist (PGD2) and in which this enzyme in turn acts as a cofacto

50 Also, levels of prostaglandin D2 (PGD2) and lipoxin A4 (LXA4) in patients with T1R were si

51 these human mast cells to secrete histamine, PGD2, and leukotriene C4 upon subsequent passive sensiti

52 d UFP-mediated increase in HETEs, HODEs, AA, PGD2, and LPA.

53 Similar polypeptide lengths of PGD1, PGD2, and PGD3 obscured which isoform may represent the

54 Other cycloxygenase products, PGE2, PGD2, and PGF2alpha, failed to activate p38 kinase in as

55 24, a DP1-selective antagonist, blocked both PGD2- and NA-induced vasodilation.

56 c acid for late, PGS2-dependent synthesis of PGD2; and (iv) a cytoplasmic PLA2-dependent step precede

57 ) and mast cell mediators (prostaglandin D2 [PGD2]) are critical activators of ILC2s.

58 These data identify PGD2 as a mediator of both the EPR and LPR in this model

59 Arachidonic acid (AA) and prostaglandin D2 (PGD2) as well as some of the lysophosphatidic acids (LPA

60 reening identified the GPCR ligands, S1P and PGD2, as factors that actively maintain the quiescent st

61 ulindac sulfide, and zomepirac displaced [3H]PGD2 binding at the mouse CRTH2 receptor (mCRTH2) with c

62 We find that PGD2 binds vertically to DP in the TM1237 region with th

63 ncomitantly induced PGHS-2 for delayed-phase PGD2 biosynthesis in activated BMMC.

64 igh levels of PGD2 and 15-deoxy-delta(12,14)-PGD2 but low levels of 15-deoxy-delta(12,14)-prostagland

65 elective CRTH2 agonist 13,14-dihydro-15-keto-PGD2 but not by the selective DP agonist BW245C, suggest

66 enzymatic rearrangement not only to PGE2 and PGD2, but also to levuglandins (LG) E2 and D2, which are

67 taxis and cytokine production in response to PGD2, but it is unknown whether ILC2s are active in pati

68 mice overexpressing human PGD2 synthase, and PGD2 can enhance Th2 cytokine production in vitro from C

69 Dermal histamine and PGD2 contractions were measured using microdialysis.

70 n peroxisomal import after dimerization, and PGD2 could be immunodetected in purified peroxisomes.

71 In addition to PGD2, CRTH2 can be activated by indomethacin, a nonselec

72 Exogenous application of PGD2 decreased WIHN in wild-type mice, and PGD2 receptor

73 r of skin regeneration, we hypothesized that PGD2 decreases follicle neogenesis.

74 cific agonist DK-PGD2 (13,14-dihydro-15-keto-PGD2) did not induce cutaneous vasodilation, and DP2-/-

75 amely, 24 h organ-cultured hHFs treated with PGD2 displayed reduced Ki-67 expression and EdU incorpor

76 (PG) receptors [EP2, EP4, prostacyclin (IP), PGD2 (DP)] and the four Gq/Gi-coupled receptors [EP1, EP

77 ceptors, shifting the role of the Langerhans/PGD2/DP1 pathway to that of an accomplice.

78 hat mRNAs corresponding to the receptors for PGD2, -E2, -F(2alpha), and -I(2) were expressed in human

79 PGD2-G, PGF2alpha-G and PGD2-EA, but not PGE2-EA or PGF2alpha-EA, also increased

80 glandin D2 synthase (Ptgds), and its product PGD2 each varied significantly among background strains

81 letion of alveolar macrophages abolished the PGD2-enhanced inflammatory response.

82 Amino-terminal deletions of PGD2 fusions with a free C terminus resulted in peroxiso

83 nflammation-related conditions, and proposes PGD2-G as a bioactive lipid with potential anti-inflamma

84 tro, as well as the 2-AG-induced increase in PGD2-G levels.

85 In addition, administration of PGD2-G reduces lipopolysaccharide-induced inflammation i

86 nflammatory prostaglandin D2-glycerol ester (PGD2-G).

87 ard PGE2-G, hABHD6 preferentially hydrolyzed PGD2-G, and human MAGL (hMAGL) robustly hydrolyzed all f

88 4)-prostaglandin J2-2-glycerol (15d-PGJ2-G), PGD2-G, PGE2-G, and PGF2 alpha-G.

89 PGD2-G, PGF2alpha-G and PGD2-EA, but not PGE2-EA or PGF2

90 ng order of activity: PGE2-G > PGF2alpha-G > PGD2-G; LYPLA2 hydrolyzed 1- but not 2-arachidonoylglyce

91 The early and late phases of PGD2 generation are mediated by prostaglandin synthase 1

92 12-epi-scalaradial, suppressed delayed-phase PGD2 generation at concentrations that did not affect im

93 Recombinant TSLP induced PGD2 generation by cultured human mast cells.

94 PGHS-2-dependent delayed-phase PGD2 generation elicited by IgE-dependent activation of

95 ein 1beta secretion, COX-2 upregulation, and PGD2 generation in mast cells.

96 arachidonic acid, its role in delayed-phase PGD2 generation is more complex and involves the activat

97 ytokine-primed, IgE-dependent, delayed-phase PGD2 generation occurred in BMMC from C57BL/6J mice, whi

98 yed phase of arachidonic acid release and of PGD2 generation was inhibited by heparin, which concomit

99 were stimulated with TSLP in vitro to assess PGD2 generation.

100 n the present study, we investigated whether PGD2 has the ability to stimulate Th2 cytokine productio

101 acid for early, PGS1-dependent synthesis of PGD2; (ii) secretory PLA2 does not play a role in the la

102 ole in the late, PGS2-dependent synthesis of PGD2; (iii) cytoplasmic PLA2 mediates the release of ara

103 unosuppressive axis by specifically blocking PGD2, IL-13 and NKp30 partially restores ILC2 and M-MDSC

104 LTE4 enhanced the effect of PGD2, IL-25, IL-33, and TSLP, resulting in increased pro

105 The effects of cysLTs, PGD2, IL-33, IL-25, TSLP, and IL-2 alone or in combinati

106 Synthesis and secretion of PGD2 in activated MMC-34 cells occurs in two stages, an

107 Proresolution functions were reported for PGD2 in colitis, but the role of its two receptors, D-ty

108 the enteric nervous system (ENS) to produce PGD2 in inflammatory conditions.

109 A significant role for PGD2 in mediating allergic responses has been suggested

110 determine the ability of the ENS to secrete PGD2 in proinflammatory conditions, Lipocalin-type prost

111 , the synergistic interaction of cysLTs with PGD2 in promoting TH2 cell activation is still poorly un

112 Instillation of PGD2 in the nose of sensitized mice together with a low

113 Thus, we hypothesized that decreases in PGD2 in the VLPO may contribute to the generalized arous

114 mplicated in the generation of both PGE2 and PGD2 in these cells by use of specific inhibitors and ef

115 e prostaglandins PGF2alpha and PGE2, but not PGD2, in rat cerebral cortical neurons in vitro.

116 Levels of racemic PGD2 increased 35-fold after treatment of rats with carb

117 PGD2 increased nonrapid eye movement sleep and induced s

118 Treatment of melanoma cell lines with PGD2 increased SOX9 expression and restored sensitivity

119 with niacin to abolish the prostaglandin D2-(PGD2)-induced flushing.

120 QAW039 was also a potent inhibitor of PGD2-induced cytokine release in human Th2 cells.

121 rthermore, Gpr44-null mice were resistant to PGD2-induced inhibition of follicle neogenesis.

122 substance, but the neuroanatomical basis of PGD2-induced sleep is only partially understood.

123 ts of common pesticides on prostaglandin D2 (PGD2) inhibition in SC5 mouse Sertoli cells, evidence of

124 In all, these findings demonstrate that PGD2 inhibits hair follicle regeneration through the Gpr

125 to identify neurons activated by infusion of PGD2 into the subarachnoid space below the rostral basal

126 ur study demonstrates that mast cell-derived PGD2 is a major effector of type 2 immune responses driv

127 Prostaglandin D2 (PGD2) is an extensively studied sleep-promoting substanc

128 atory cells in response to prostaglandin D2 (PGD2), is hypothesized to play a role in Th2-mediated al

129 demonstrate that PGF2alpha, but not PGE2 or PGD2, is necessary but not sufficient for NMDA induction

130 Stimulation by PGD2 led to phosphorylation of CREB, but had negligible

131 DS mRNA expression, and significantly higher PGD2 levels than healthy colonic mucosa.

132 l correlated such that the highest Ptgds and PGD2 levels were associated with the lowest amount of re

133 PGD2 levels were determined in a medium of primary cultu

134 PGD2 levels were significantly increased on primary cult

135 f NS398 and estradiol significantly elevated PGD2 levels.

136 nd LTE4 were observed in AERD (at 60 min for PGD2 , LTD4 , and LTE4 ) but not in MNSAID-UA or control

137 enge were analyzed for ECP, tryptase, PGE2 , PGD2 , LTD4 , and LTE4 .

138 Significant increases in PGD2 , LTD4 , and LTE4 were observed in AERD (at 60 min

139 aimed to comprehensively define the roles of PGD2, LTE4, and their combination in activating human TH

140 The effects of PGD2, LTE4, and their combination on human TH2 cell gene

141 For the first time, our results show that PGD2 markedly augments disease activity through its abil

142 These observations suggest that PGD2 may induce sleep via leptomeningeal PGD2 receptors

143 We investigated the expression of PGD2 metabolic pathway actors in Crohn's disease (CD) an

144 Expression of key actors involved in the PGD2 metabolic pathway and its receptors was analyzed us

145 Our results highlight the activation of the PGD2 metabolic pathway in Crohn's disease.

146 e of the importance of the prostaglandin D2 (PGD2) metabolic pathway in inflammatory bowel diseases.

147 Urinary levels of a stable PGD2 metabolite (uPGD-M) were 2-fold higher in patients

148 s concerning prostaglandin E2 (PGE2) and the PGD2 metabolite 15-deoxy-Delta(12,14)-PGJ2, and their di

149 ne was also collected, and quantification of PGD2 metabolite and leukotriene E4 levels was done by us

150 rently with significant increases in urinary PGD2 metabolite and leukotriene E4 levels.

151 These PGD2 metabolites activated the PPARgamma ligand-binding

152 ssion of PPARgamma-expressing tumor cells by PGD2 metabolites in the prostate microenvironment is lik

153 in D synthase (L-PGDS) and prostaglandin D2 (PGD2) metabolites produced by normal prostate stromal ce

154 achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL-13 and M-MDSCs are restored.

155 th or without OVA to determine the effect of PGD2 on nasal responsiveness.

156 mmunization and then was boosted with either pgD2 or MVA-gD2.

157 ntrast, the time course of prostaglandin D2 (PGD2) or 9 alpha, 11 beta PGF2 (11 beta PGF2) formation

158 1 beta-PGF2 alpha but was unchanged by 10 nM PGD2, PGE2, PGF1 alpha, carbaprostacyclin, U-46619, or 1

159 clone catalyzed the transport of PGE1, PGE2, PGD2, PGF2alpha, and, to a lesser degree, TXB2.

160 misoprostol but not with 10(-6) M PGF2alpha, PGD2, PGI2, or butaprost, suggesting a principal depende

161 Prostaglandin D2 (PGD2 ) plays an important role in allergic inflammation.

162 ons found at sites of allergic inflammation, PGD2 preferentially elicited the production of IL-4, IL-

163 These data suggest that PGD2 preferentially up-regulates proinflammatory cytokin

164 y represented approximately 30% of the total PGD2 present in urine.

165 n-2 and interferon-gamma than did those from pgD2-primed mice, indicating that a prime-boost immuniza

166 h MVA-gD2 and boosted with either MVA-gD2 or pgD2 produced higher levels of interleukin-2 and interfe

167 PGD2, produced by mast cells, has been detected in high

168 also able to inhibit both the early phase of PGD2 production and the secretion of PLA2 activity by ac

169 , (ii) group V PLA2 mediates early mast cell PGD2 production and transcellular PGE2 production in mur

170 PLA2 activation and is necessary for optimal PGD2 production by the secretory PLA2/PGS1-dependent ear

171 PGE2 synthesis, at the same time decreasing PGD2 production in a reciprocal fashion.

172 Gpr44 receptor and imply that inhibition of PGD2 production or Gpr44 signaling will promote skin reg

173 PGE2 production was suppressed by ibuprofen, PGD2 production was not.

174 y thromboxane B2, prostaglandin (PG) E2, and PGD2 production, in addition to lysophospholipid acyltra

175 l, pyrimethanil, and tebuconazole suppressed PGD2 production.

176 15-epi-LXA4 or MaR1 down-regulated PGE2 and PGD2 production.

177 he ENS, ECG and neurons, could contribute to PGD2 production.

178 PGD2 promotes the growth of retinal capillary pericytes

179 Two PGD2 receptors have been identified: PGD2 receptor 1 (DP1, also called DP) and PGD2 receptor

180 d: PGD2 receptor 1 (DP1, also called DP) and PGD2 receptor 2 (DP2, sometimes termed CRTH2).

181 f PGD2 decreased WIHN in wild-type mice, and PGD2 receptor Gpr44-null mice showed increased WIHN comp

182 d pulmonary inflammation, activation of each PGD2 receptor resulted in aggravated airway neutrophilia

183 The PGD2 receptor, CRTH2, is expressed on basophils, eosinop

184 ene acid 1-E to give 2, a prostaglandin D2 (PGD2) receptor antagonist.

185 Two PGD2 receptors have been identified: PGD2 receptor 1 (DP

186 Activation of PGD2 receptors on human macrophages enhanced the migrato

187 We investigated the role of PGD2 receptors on primary human macrophages, as well as

188 hat PGD2 may induce sleep via leptomeningeal PGD2 receptors with subsequent activation of the VLPO.

189 receptors caused a marked increase in AA and PGD2 release after stimulation of BMMC, implicating sPLA

190 ast cells with measurements of Ca2+ flux and PGD2 release.

191 an mast cells directly through Ca2+ flux and PGD2 release.

192 ate in the cytosol and chloroplasts, whereas PGD2 remains in the cytosol.

193 Further, VIP induced PGD2 secretion from eosinophils.

194 Changes in PGD2 secretion in juvenile mouse Sertoli cells (SC5 cell

195 or the COX inhibitors alone had an effect on PGD2 serum levels, co-administration of NS398 and estrad

196 ht arise from simultaneous interference with PGD2 signaling and androgen action.

197 PGE2 and PGD2 specifically reduced the proportion of macrophages

198 9 behaved as an insurmountable antagonist of PGD2-stimulated [(35)S]-GTPgammaS activation, and its ef

199 All CRTh2 antagonists tested inhibited PGD2-stimulated human eosinophil shape change, but impor

200 angerhans cells to produce prostaglandin D2 (PGD2), stimulating vascular DP1 receptors to cause vasod

201 ast cells sorted from nasal polyps expressed PGD2 synthase (hematopoietic PGD2 synthase) mRNA at high

202 ed strongly with mRNA encoding hematopoietic PGD2 synthase (r = .75), the mast cell-specific marker c

203 olyps expressed PGD2 synthase (hematopoietic PGD2 synthase) mRNA at higher levels than did eosinophil

204 2 and PGE2 synthase, between COX-1/COX-2 and PGD2 synthase, and also between COX-1 and thromboxane A2

205 ways of transgenic mice overexpressing human PGD2 synthase, and PGD2 can enhance Th2 cytokine product

206 paper that lipocalin-type prostaglandin D2 (PGD2) synthase (L-PGDS) interacts intracellularly with t

207 Surprisingly, PGD2 synthesis by L-PGDS is promoted by coexpression of

208 Early phase PGD2 synthesis in activated mast cells also requires the

209 ate most of the pesticides shown to suppress PGD2 synthesis.

210 e Pla2 g2a gene both demonstrate early phase PGD2 synthesis.

211 varied than previously thought can suppress PGD2 synthesis.

212 ic PGD synthase, the rate-limiting enzyme of PGD2 synthesis.

213 Prostaglandin D2 (PGD2) synthesis in activated mast cells occurs in two ph

214 European Union to suppress prostaglandin D2 (PGD2) synthesis.

215 ucted to determine the site of action in the PGD2 synthetic pathway.

216 (PG) release from RASMCs, including that of PGD2, the precursor of the putative endogenous PPARgamma

217 gest that TNFalpha induced a switch from the PGD2 to PGE2 synthesis pathway by regulating PGE2 syntha

218 the binding mode for the endogenous agonist (PGD2) to DP.

219 Repeated selfing of pgd2 transfer (T-)DNA alleles yielded no homozygous muta

220 PGD2 treatment induced c-fos mRNA, stimulated pericyte g

221 We report here that an inflammatory PG, PGD2, via its receptor, mediates the activation of NF-ka

222 PGD2 was administered with or without OVA to determine t

223 The effect of PGD2 was mimicked by the selective CRTH2 agonist 13,14-d

224 of the natural prostaglandins PGF2alpha and PGD2 was not enhanced by the mutations.

225 PGE2 and PGD2 were elevated early and late, respectively, during

226 rawal latencies and serum levels of PGE2 and PGD2 were measured in rats treated with estradiol (0, 10

227 P receptor agonists U-46,619, PGF2alpha, and PGD2 were more potent than PGE2.

228 Racemic PGE2 and PGD2 were present esterified in phospholipids derived fr

229 the groups, but levels of LTD4 , LTE4 , and PGD2 were significantly higher in AERD group.

230 In addition, racemic PGs, particularly PGD2, were present unesterified in urine from normal ani

231 thermore, we also show how prostaglandin D2 (PGD2), which is upregulated in balding scalp, differenti

232 inhibited Th2 cytokine production induced by PGD2, while the selective thromboxane-like prostanoid re

233 tosolic and/or plastidic enzyme plus whether PGD2 with a peroxisomal targeting motif also might targe